# A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Source: https://onco.cc/trials/nct05483868/  
OnCo record `nct05483868` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Belzupacap sarotalocan run by Aura Biosciences, active and no longer recruiting.

## Summary

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer is a phase 1 interventional study registered as NCT05483868 by Aura Biosciences, with 55 participants planned, started 2022-09-26. Conditions recorded: Non-muscle-invasive Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms, Non-Muscle Invasive Bladder Urothelial Carcinoma and Urothelial Carcinoma Bladder. Interventions recorded: AU-011, AU-011 in Combination with Medical Laser Adminstration and AU-011 in Combination with Medical Laser Administration.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05483868
- Phase: 1
- Setting: A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) to Determine the Feasibility and Safety of Intratumoral Injection With or Without Intramural Injection in Subjects With Bladder Cancer
- Sponsor: Aura Biosciences
- Enrolled: 55

## Sources

- ClinicalTrials.gov NCT05483868: https://clinicaltrials.gov/study/NCT05483868

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Non-muscle-invasive bladder cancer](https://onco.cc/cancers/non-muscle-invasive-bladder-cancer/)
- drugs: [Belzupacap sarotalocan](https://onco.cc/drugs/belzupacap-sarotalocan/)
- companies: [Aura Biosciences](https://onco.cc/companies/aura-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct05483868.json